Pulmonary Hypertension Associated with Bronchiolitis Obliterans after Stem Cell Transplant  by Dandoy, Christopher E. et al.
Table
Demographics and outcomes of patients a BSI after SCT. 13 patients had >1 infection accounting for 39 total infections.
MBI-LCBI (n¼18) CLABSI
(n¼20)
Secondary BSI
(n¼13)
> 1 BSI after HSCT
(n¼13 patients)
Mean age (years) at SCT (Range) 7.1 (0.9-28.7) 4.6 (0.3-29.8) 5.4 (0.9-32.8) 9.2 (2.2-27.5)
Median days from SCT to BSI (IQR) 7 (4-55) 59 (8-137) 70 (48-118) 149 (58-313)
Diagnosis
Immune Deﬁciency (n¼32)
Malignancy (n¼17)
Marrow Failure (n¼8)
Benign Hematology (n¼5)
Genetic/Metabolic (n¼2)
8 (44%) 13 (65%) 4 (31%) 7 (54%)
6 (33%) 5 (25%) 3 (23%) 3 (23%)
2 (11%) 0 3 (23%) 3 (23%)
1 (6%) 1 (5%) 3 (23%) 0
1(6%) 1 (5%) 0 0
Myeloablative conditioning (n¼28) 8 (44%) 12 (60%) 5 (38%) 3 (23%)
GVHD (Grade II-IV) at 100 days (n¼19) 4 (22%) 5 (25%) 6 (46%) 4 (31%)
Sepsis/shock (n¼31) 4 (22%) 10 (50%) 3 (23%) 14 (36%)
ICU care within 7 days of BSI (n¼15) 4 (22%) 4 (20%) 3 (23%) 4 (10%)
Died (n¼27) 8 (44%) 8 (40%) 3 (23%) 8 (62%)
Non relapsed mortality (n¼20) 6 (33%) 6 (30%) 3 (23%) 5 (38%)
Median days from BSI to death (IQR) 90 (51-152) 119 (50-206) 44 (34-63)
In patients with > 1 BSI, median days from
last BSI to death (IQR)
156 (113-302)
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2011 to April 2014 at our center to determine the timing,
underlying diagnosis, and outcomes of patients diagnosed
with MBI-LCBIs, CLABSIs and secondary BSIs after stem cell
transplant (SCT). We applied the newMBI-LCBI classiﬁcation
to patients undergoing SCT prior to NHSN criteria
implementation.
Results: 299 patients underwent SCT during the 36-month
study period. 34 CLABSIs, 30 MBI-LCBIs, and 26 secondary
BSIs were diagnosed in 64 patients (21%). Thirteen patients
(20%) had more than one infection accounting for 39 of the
90 (43%) infections. MBI-LCBIs occurred shortly after SCT at a
median of 7 days after transplant. 11 of 14 patients with MBI-
LCBIs after day +30 (including patients with > 1 infection)
were diagnosed with GVHD, with 10/11 having GI-GVHD.
Conclusions: One third of BSIs were classiﬁed as an MBI-
LCBI. MBI-LCBIs occurred earlier after SCT than CLABSIs and
secondary BSIs, likely due to mucositis, and were associated
with GVHD after day +30. As the MBI-LCBI classiﬁcation is
new, further research is needed to understand the patho-
genesis and prevention of MBI-LCBIs.Table
Patients diagnosed with BO and PH after HSCT
Diagnosis Age
at SCT
(years)
Days from
SCT to
diagnosis
of BO
Days from
SCT to
diagnosis
of PH
Days from
SCT to death
WiskottAldrich 0.6 233 235 Alive
AML 17.4 305 351 352
CML 10.4 158 247 1368
Aplastic Anemia 5.4 131 No diagnosis
of PH
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Background: Bronchiolitis obliterans (BO) and pulmonary
hypertension (PH) are rare and fatal complications of stem
cell transplantation (SCT). BO is a non-reversible obstructive
lung disease in which bronchioles are compressed and nar-
rowed by ﬁbrosis and/or inﬂammation. PH arises fromincreased pulmonary vascular resistance leading to
increased right ventricular pressure, right heart failure, and
death. PH has not been described in patients with BO after
SCT.
Design/Methods: To evaluate PH in patients with BO, we
retrospectively reviewed all cases of BO in 291 patients un-
dergoing allogeneic HSCT from January 2009 to December of
2012. Patients diagnosed with BO met standard criteria for
BO diagnosis including high resolution CT evidence of air-
trapping. PH was diagnosed with echocardiography, cardiac
catheterization, and autopsy.
Results: Four patients (1.4%) were diagnosed with BO. All
four patients had a history of graft versus host disease, no
infectious cause of respiratory symptoms, and high resolu-
tion CT evidence of BO. Two patients received PFT testing
which showed decreased FEV1. All patients received serial
echocardiography after SCT. Three of the four patients were
diagnosed with PH after the diagnosis of BO (Table). All three
patients had elevated estimated right ventricular pressure,
with secondary signs of PH, on echocardiography. One pa-
tient underwent cardiac catheterization conﬁrming PH, and
one had ﬁndings consistent with PH on autopsy (Figure).
Two patients died from respiratory failure, both received
inhaled nitric oxide. The surviving patient with PH and BO
required intermittent non-invasive ventilation and was
treated with sildenaﬁl for PH. The patient without PH died
192 days after SCT.
Conclusion: PH has not been described in patients with BO
after SCT. The etiology of PH after BO is unclear; however,
parenchymal changes in BO may lead to pulmonary vascular
injury and hypertrophy. Also, long-term hypoxemia and
inﬂammation can lead to vasoconstriction, vascular remod-
eling and angiogenesis, which in turn leads to increased
Figure. Pulmonary arteriole intimal and medial thickening seen in a patient
with bronchiolitis obliterans
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with BO may assist in diagnosing PH. The treatment for PH
differs from BO and there is little understanding of their
interplay post-HSCT; further investigation is needed.291
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Background: Posterior reversible encephalopathy syndrome
(PRES) is a clinical syndrome characterized by vision
changes, alteredmental status, and seizures that are typically
caused by acute rise in blood pressure and resolve over time.
PRES has been reported after stem cell transplant (SCT) in
association with hypertension from calcineurin inhibitors
and steroids. The radiologic evaluation of PRES after SCT has
not been well described.
Design/Methods: A retrospective review of all cases of PRES
in SCT recipients from January of 2004 to December of 2013
was performed. PRES was diagnosed if the patient developed
encephalopathy, headache, seizures or visual disturbances
with a CT and/or MRI showing imaging ﬁndings compatible
with PRES.
Results: Twenty-two of 838 (2.6%) transplanted patients
were diagnosed with PRES, all of them allogeneic SCT re-
cipients. The majority (64%) were male with a median age of9.4 years (IQR 4.9-12.1) at time of SCT. Nine patients had a
marrow failure syndrome (41%), 7 of which had Fanconi
Anemia; 7 patients had an immune deﬁciency (32%); 5 had
an underlying malignancy (23%); and 1 patient had a meta-
bolic syndrome (4%). Twelve patients (55%) had a myeloa-
blative preparative regimen. All patients received
cyclosporine for graft versus host disease prophylaxis after
SCT and 11 (50%) were treated with additional immunosu-
pressants including steroids for GVHD at the time of event.
PRES was diagnosed at a median of 49 days (IQR 31-88) after
SCT. Nineteen patients (86%) presented with seizures, the
other 3 (14%) had altered mental status. All patients under-
went a brain CT and/or MRI, 21 of 22 patients (95%) received
a CT scan when they became symptomatic, which was
diagnostic of PRES in 8 of the 21 studies (38%). Eighteen
patients (82%) received MRI, 17 of the 18 (96%) were
consistent with PRES. The one MRI not consistent with PRES
was done 20 days after initial diagnosis, subsequent to res-
olution of the abnormal CT ﬁndings. Notably in 13 patients
initial CT scans did not demonstrate ﬁndings of PRES, which
were subsequently found on MRI. The median time elapsed
between CT and an MRI examination was 20 hours (range:
3.6 hours to 9 days). The overall survival in patients that
developed PRES was 35% (8 of 23 survived).
Conclusion: CT scan serves as a good diagnostic test in
emergency situations to rule out CNS bleed or infection in
SCT patients with acute mental status changes or seizures,
but it is not an adequate radiologic study for diagnosing of
PRES after SCT. Patients with clinical symptoms suggestive of
PRES, but negative CT, should undergo MRI of the brain after
the acute event is controlled to assist in diagnosis. MRI re-
sults diagnostic of PRES would prompt physicians to provide
good hypertension control and aid decision-making
regarding invasive diagnostic procedures (like lumbar
puncture) or intensiﬁcation of empiric antimicrobial therapy.292
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Background: The gut microbiome is an important immune
modulator, and previous work has shown important changes
in the gut microbiome associated with the occurrence of
GVHD. Studies in premature babies at risk for necrotizing
enterocolitis have shown that enteral human milk reduces
gut inﬂammation and bacterial translocation (Morrow et al,
2012).We hypothesized that enteral humanmilk given in the
peri-transplant period would be well tolerated and would
modify the microbiome and reduce inﬂammation.
Methods: In a pilot study, we treated 10 children<2 yrs with
donor enteral milk, and collected stool samples for micro-
biome analysis and blood samples for analysis of inﬂamma-
tory markers. Milk was obtained from the Mother’s Milk
Bank of the Northeast. Milk donors underwent standard
donor screening and milk was pasteurized before use. As
prebiotic and anti-inﬂammatory beneﬁts of are thought to
derive from human milk oligosaccharides produced by
fucosyltransferase2 (FUT2) and related gene biosynthesis
